NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Aramis Biosciences, Inc.

Aramis Biosciences, Inc.

Private
Medfield, MassachusettsHealthcare & Life Scienceshttps://aramisbio.com/

Last Round

Series A

Dec 15, 2021

Total Funding Raised

$19.5M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Aramis Biosciences, Inc. is a clinical-stage immuno-ophthalmology biopharmaceutical company developing disease-modifying therapies for ocular surface diseases such as Dry Eye Disease.

Sector

Healthcare & Life Sciences

Verticals

Clinical Trials, Drug Discovery, Biotechnology

Business Model

B2B2C

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

dry eye diseasedry eye treatmentimmuno-ophthalmologyclinical-stage biopharmabiotechdisease-modifying therapyIL-17A antagonistfirst-in-class therapyimmunomodulatory agentocular surface diseasedrug developmenttopical therapyophthalmic solutionAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aramis Biosciences, Inc. Comps

Public and private peers based on sector, stage, and business model.

Aramis Biosciences, Inc. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Aramis Biosciences, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 15, 2021
View all Funding Rounds

Key People

Founding team and executive leadership

David Lacey

Chief Operating Officer

Executive Team

Aramis Biosciences, Inc. Investors

Notable investors and investment history

Aramis Biosciences, Inc. investors
InvestorRounds
Safar PartnersSeries A
Santen VenturesSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors grew 259% MoM, reaching 1.1K.

  • Jan 9, 2026

    Monthly visitors increased 572% MoM.

View all signals

Aramis Biosciences, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aramis Biosciences, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aramis Biosciences, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersMedfield, Massachusetts
Employee Range3
Year Founded2018
Last FundingDec 15, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.